HIGHLIGHTS
- who: Anne L. Plant from the is largely attributable to complex and highly manual manufacturing processes, variability in donor and patient cells, reagent quality variability, and the lack of standards and comparability metricsData sharing and standardization could alleviate these issues and significantly improve outcomes in trials with RMAT products. Finally, the regenerative medicine workforce should be cognizant of the legal challenges of data sharing related to intellectual property and how data sharing may impact the security of patient data28, . Data sharing could substantially advance the field but remains contingent on appropriate data management and security practices have . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.